BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Thurow HS, Hartwig FP, Alho CS, Silva DS, Roesler R, Abujamra AL, de Farias CB, Brunetto AL, Horta BL, Dellagostin OA, Collares T, Seixas FK. Ewing Sarcoma: influence of TP53 Arg72Pro and MDM2 T309G SNPs. Mol Biol Rep 2013;40:4929-34. [PMID: 23661019 DOI: 10.1007/s11033-013-2593-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Martinelli M, Mancarella C, Scapoli L, Palmieri A, De Sanctis P, Ferrari C, Pasello M, Zucchini C, Scotlandi K. Polymorphic variants of IGF2BP3 and SENCR have an impact on predisposition and/or progression of Ewing sarcoma. Front Oncol 2022;12:968884. [DOI: 10.3389/fonc.2022.968884] [Reference Citation Analysis]
2 Gargallo P, Yáñez Y, Juan A, Segura V, Balaguer J, Torres B, Oltra S, Castel V, Cañete A. Review: Ewing Sarcoma Predisposition. Pathol Oncol Res 2020;26:2057-66. [PMID: 31656020 DOI: 10.1007/s12253-019-00765-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
3 Huang X, Wu F, Zhang Z, Shao Z. Association between TP53 rs1042522 gene polymorphism and the risk of malignant bone tumors: a meta-analysis. Biosci Rep 2019;39:BSR20181832. [PMID: 30833364 DOI: 10.1042/BSR20181832] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
4 Benna C, Simioni A, Pasquali S, De Boni D, Rajendran S, Spiro G, Colombo C, Virgone C, DuBois SG, Gronchi A, Rossi CR, Mocellin S. Genetic susceptibility to bone and soft tissue sarcomas: a field synopsis and meta-analysis. Oncotarget 2018;9:18607-26. [PMID: 29719630 DOI: 10.18632/oncotarget.24719] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
5 Sampson VB, Vetter NS, Kamara DF, Collier AB, Gresh RC, Kolb EA. Vorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK Pathways. PLoS One 2015;10:e0142704. [PMID: 26571493 DOI: 10.1371/journal.pone.0142704] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
6 Zhang D, Ding Y, Wang Z, Wang Y, Zhao G. Impact of MDM2 gene polymorphism on sarcoma risk. Tumour Biol 2015;36:1791-5. [PMID: 25366142 DOI: 10.1007/s13277-014-2781-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
7 Xu H, Zhou P, Ti Y, Jia F. Quantitative assessment of the association between HDMX polymorphism and sarcoma. Cell Biochem Biophys 2014;70:1671-6. [PMID: 24972690 DOI: 10.1007/s12013-014-0111-5] [Reference Citation Analysis]
8 Hartwig FP, Entiauspe LG, Nunes EM, Rodrigues FM, Collares T, Seixas FK, da Silveira MF. Evidence for an epistatic effect between TP53 R72P and MDM2 T309G SNPs in HIV infection: a cross-sectional study in women from South Brazil. PLoS One 2014;9:e89489. [PMID: 24586820 DOI: 10.1371/journal.pone.0089489] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
9 Chang Z, Yu X. Association between p53 codon 72 polymorphism and sarcoma risk among Caucasians. Tumor Biol 2014;35:4807-12. [DOI: 10.1007/s13277-014-1631-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]